3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Lung Neoplasms
3
Neoplasm Metastasis
2
Cholangiocarcinoma
2
Biliary Tract Neoplasms
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Tertiary Lymphoid Structures
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma
1
Recurrence
1
Nasopharyngeal Carcinoma
1
Mesothelioma, Malignant
1
Mesothelioma
1
Gallbladder Neoplasms
1
Castration Resistant Prostate Cancer
1
Carcinoma, Transitional Cell
1
Camurati-Engelmann Syndrome
1
Breast Neoplasms
1
Interventions
pembrolizumab
31
Gemcitabine
26
Nivolumab
20
atezolizumab
16
Cisplatin
15
avelumab
14
Carboplatin
12
Docetaxel
10
enfortumab vedotin
8
Magnetic Resonance Spectroscopy
8
durvalumab
7
Specimen Handling
7
Paclitaxel
7
Ipilimumab
6
toripalimab
5
pemigatinib
5
cabozantinib
5
vinflunine
4
sacituzumab govitecan
4
Taxes
4
Pemetrexed
4
tislelizumab
3
cabazitaxel
3
Standard of Care
3
Mitomycin
3
Injections
3
Everolimus
3
Albumin-Bound Paclitaxel
3
sapanisertib
2
olaparib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Carcinoma, Transitional Cell
×
bintrafusp alfa protein, human
×
Clear all
NCT04878250
2021-05-07
PEBBLE
Queen Mary University of London
Phase 2
Unknown
49 enrolled